Takeda released a press statement today announcing the establishment of the Shanghai Development Center (“TSDC”) within the Shanghai-based Takeda (China) Holdings Co., Ltd. (“TCH”), which is a wholly owned subsidiary of Takeda.
This new drug development center in Shanghai is intended to complement the international clinical work now under way in Singapore and Cambridge, MA.
Both of the existing operations, including the cancer drug developer Millennium in Cambridge, work with contract research organizations to advance new treatments through the clinic. Now the Shanghai operation will draw on the international team to study new drugs catering to the fast-growing market in China.
The establishment of [the Takeda Shanghai Development Center] will provide a powerful addition to this global development infrastructure,” the company stated today. Through the resources of TSDC, Takeda will continue to conduct high quality clinical trials which will lead to secure regulatory approval in Asia, with a growing emphasis on China, and continue to build deeper relationships with physicians and regulatory authorities.”